Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: November 5, 2025
Principal Executive Offices: Hingham, MA
This filing announces a significant commercial milestone for the Company's primary product, the LIBERTY® Endovascular Robotic System.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate event rather than financial performance results.
Material Changes
- Commercial Availability: The LIBERTY® Endovascular Robotic System is now commercially available in the United States on a limited basis.
- Market Strategy: The limited market release targets selected high procedure volume regions where the Company has already observed preliminary demand.
Guidance, Outlook, and Risks
Management Commentary: The Company is introducing the system to regions with existing preliminary demand to facilitate the commercial launch.
Forward-Looking Statements: The filing contains forward-looking statements regarding regulatory milestones, beliefs, plans, and expectations. The Company explicitly states that actual results could differ materially from projections due to numerous factors.
Risks and Contingencies: Investors are directed to consult risk factors disclosed in other SEC filings. The Company assumes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the specific geographic regions included in the "limited basis" commercial release.
- Review the full text of the press release (Exhibit 99.1) for details on pricing, distribution partners, or initial order volumes.
- Assess the timeline for expanding commercial availability beyond the initial limited regions.
- Consult the Company's most recent 10-K or 10-Q filings for current liquidity and cash burn rates, as this 8-K does not contain financial statements.